← Back to Screener
IQVIA Holdings Inc. (IQV)
Price$171.95
Favorite Metrics
Price vs S&P 500 (26W)-15.20%
Price vs S&P 500 (4W)0.81%
Market Capitalization$30.22B
P/E Ratio (Annual)22.22x
All Metrics
P/CF (Annual)11.39x
Book Value / Share (Quarterly)$38.34
P/TBV (Annual)24.91x
Revenue Growth (3Y)4.21%
Cash Flow / Share (Quarterly)$12.09
Price vs S&P 500 (YTD)-23.63%
Gross Margin (TTM)33.29%
Net Profit Margin (TTM)8.34%
EPS (TTM)$7.86
10-Day Avg Trading Volume1.31M
EPS Excl Extra (TTM)$7.86
Revenue Growth (5Y)7.50%
EPS (Annual)$7.84
ROI (Annual)6.06%
Gross Margin (Annual)33.29%
Net Profit Margin (5Y Avg)8.17%
Cash / Share (Quarterly)$12.62
P/E Basic Excl Extra (TTM)22.22x
Revenue Growth QoQ (YoY)10.26%
EPS Growth (5Y)40.52%
P/E Normalized (Annual)22.22x
ROA (Last FY)4.54%
Revenue Growth TTM (YoY)5.87%
EBITD / Share (TTM)$19.71
ROE (5Y Avg)20.13%
Operating Margin (TTM)13.34%
Cash Flow / Share (Annual)$12.09
P/B Ratio4.65x
P/B Ratio (Quarterly)5.90x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.70x
Net Interest Coverage (TTM)3.33x
ROA (TTM)4.75%
EPS Growth QoQ (YoY)23.78%
EV / EBITDA (TTM)12.86x
EPS Incl Extra (Annual)$7.84
Current Ratio (Annual)0.75x
Quick Ratio (Quarterly)0.73x
3-Month Avg Trading Volume1.85M
52-Week Price Return18.01%
EV / Free Cash Flow (Annual)21.44x
P/E Incl Extra (TTM)22.22x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$9.09
P/S Ratio (Annual)1.85x
Asset Turnover (Annual)0.54x
52-Week High$247.05
Operating Margin (5Y Avg)12.62%
EPS Excl Extra (Annual)$7.84
CapEx CAGR (5Y)-0.43%
Tangible BV CAGR (5Y)14.12%
26-Week Price Return-11.22%
Quick Ratio (Annual)0.73x
13-Week Price Return-26.06%
Total Debt / Equity (Annual)2.45x
Current Ratio (Quarterly)0.75x
Enterprise Value$43,967.568
Revenue / Share Growth (5Y)10.04%
Asset Turnover (TTM)0.57x
Book Value / Share Growth (5Y)4.06%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)9.75%
Cash / Share (Annual)$12.62
3-Month Return Std Dev47.12%
Gross Margin (5Y Avg)34.30%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)10.56%
EBITDA Interim CAGR (5Y)10.18%
ROE (Last FY)20.91%
Net Interest Coverage (Annual)3.33x
EPS Basic Excl Extra (Annual)$7.84
P/FCF (TTM)14.74x
Receivables Turnover (TTM)4.94x
EV / Free Cash Flow (TTM)21.44x
Total Debt / Equity (Quarterly)2.42x
EPS Incl Extra (TTM)$7.86
Receivables Turnover (Annual)4.94x
ROI (TTM)6.41%
P/S Ratio (TTM)1.85x
Pretax Margin (5Y Avg)9.58%
Revenue / Share (Annual)$94.01
Tangible BV / Share (Annual)$9.09
Forward P/E13.53x
Free OCF CAGR (5Y)8.84%
Price vs S&P 500 (52W)-11.82%
P/E Ratio (TTM)22.22x
EPS Growth TTM (YoY)4.84%
Year-to-Date Return-20.99%
5-Day Price Return5.40%
EPS Normalized (Annual)$7.84
ROA (5Y Avg)4.59%
Net Profit Margin (Annual)8.34%
Month-to-Date Return4.43%
Cash Flow / Share (TTM)$12.15
EBITD / Share (Annual)$19.71
EPS Growth (3Y)11.13%
Operating Margin (Annual)13.34%
LT Debt / Equity (Annual)2.13x
P/CF (TTM)11.39x
ROI (5Y Avg)6.14%
P/E Excl Extra (TTM)22.22x
LT Debt / Equity (Quarterly)2.13x
EPS Basic Excl Extra (TTM)$7.86
P/TBV (Quarterly)24.91x
P/B Ratio (Annual)5.90x
Pretax Margin (TTM)9.75%
Book Value / Share (Annual)$38.34
Price vs S&P 500 (13W)-26.74%
Net Margin Growth (5Y)27.66%
Beta1.32x
P/FCF (Annual)14.74x
Revenue / Share (TTM)$94.99
ROE (TTM)22.28%
52-Week Low$134.65
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.13
4.13
4.19
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
IQVIQVIA Holdings Inc. | 22.22x | 22.28% | 7.50% | — | $171.95 |
INCYIncyte Genomics Inc | 14.67x | 29.15% | 14.03% | — | $95.32 |
MEDPMedpace Holdings, Inc. Common Stock | 32.83x | 118.82% | 22.27% | — | $515.65 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $176.94 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.23 |
NRCNational Research Corporation Common Stock (Delaware) | 34.98x | 58.51% | 0.61% | 3.59% | $17.62 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.56 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.82 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.30 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.12 |
About
IQVIA provides outsourced clinical trial services and healthcare data analytics to the global pharmaceutical and healthcare industries. The company operates through two segments: Research & Development, offering late-stage clinical trials to pharmaceutical, medical device, and diagnostic companies; and Technology & Analytics, delivering aggregated data and analytics solutions to pharmaceutical firms, healthcare providers, payers, and policymakers.